智飛生物(300122.SZ):重組新冠病毒疫苗(CHO細胞)正處於Ⅰ、Ⅱ期臨牀試驗過程中
格隆匯 7 月 23日丨智飛生物(300122.SZ)公佈,公司2020年7月21日、7月22日、7月23日連續3個交易日內日收盤價格漲幅偏離值累計超過20%,根據深圳證券交易所的有關規定,屬於股票交易異常波動的情況。
公司於2020年6月23日發佈了《關於新型冠狀病毒疫苗獲得臨牀試驗批件的公告》,公告重組新型冠狀病毒疫苗(CHO細胞)獲得了臨牀受理通知書及臨牀試驗批件,並按照臨牀批件的要求開展臨牀試驗工作。
公司與中國科學院微生物研究所合作研發的重組新型冠狀病毒疫苗(CHO細胞)目前正處於Ⅰ、Ⅱ期臨牀試驗過程中。
疫苗研製是非常複雜嚴謹的科學活動,難度大、週期長,產品研發、註冊進度和結果存在一定的不確定性。公司將嚴格按照有關法律法規的規定和要求,認真履行信息披露義務,及時做好信息披露工作。敬請廣大投資者理性投資,注意風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.